Biliary Tract Neoplasms Clinical Trial
— PREVAILctDNAOfficial title:
Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
NCT number | NCT04566614 |
Other study ID # | CCR 5292 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 18, 2020 |
Est. completion date | December 31, 2025 |
The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.
Status | Recruiting |
Enrollment | 294 |
Est. completion date | December 31, 2025 |
Est. primary completion date | July 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants aged =18 years old - Patients with suspected malignancies of early stage colorectal cancer (FIT intermediate and high risk), early and late stage pancreatic cancer, biliary tract cancer, gastro-intestinal stromal tumours, lung cancer or bladder cancer, without a definitive histological diagnosis (including those with inconclusive biopsy result) or - Patients with histological diagnosis of lung cancer without adequate tissue for NHS genomic test directory predictive biomarker testing - Ability to provide informed consent. - Patients with performance status suitable for oncological treatments (ECOG performance status 0-2). Exclusion criterion: • Patients with an established histological diagnosis adequate to support standard of care treatment PART 2: Inclusion criteria - Included in the ACCESS implementation programme - Has detectable ctDNA on Guardant360© assay - Discussion at molecular tumour board and central multi-disciplinary meeting confirming ctDNA variant is supportive of diagnosis of PC/BTC (diagnostic or consistent with) - Performance status suitable for oncological treatment - Ability to provide informed consent Exclusion criteria 1. Previously diagnosed invasive or haematological malignancy within the past 3 years 2. Outcome at the molecular tumour board not supportive of cancer diagnosis (possibly consistent or not consistent) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Marsden Hospital | Sutton | Surrey |
Lead Sponsor | Collaborator |
---|---|
Royal Marsden NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ctDNA detection rate within different cancer types (and overall) | The primary endpoint, ctDNA detection rate, overall and within different cancer types will be presented as a proportion of patients with a positive ctDNA test out of those tested, with 90% confidence intervals | Throughout study completion, up to one year | |
Primary | PREVAIL ctDNA Part 2 Study | Primary end point, Proportion of patients with detectable ctDNA which supports a diagnosis of malignancy and commence treatment | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | Proportion of patients with a positive ctDNA result which identified a diagnosis and/or commenced treatment | All secondary endpoints will be analysed in the patients diagnosed with suspected cancer, i.e. positive ctDNA result, unless stated. They will also be presented overall and by cancer type. The proportion of patients with positive ctDNA result which identified a diagnosis and/or commenced treatment will be presented as a proportion with 90% confidence intervals | Throughout study completion, up to one year | |
Secondary | Proportion of patients with a positive ctDNA result which assisted in prioritising invasive diagnostic tests | Proportion of patients with positive ctDNA result which assisted in prioritising invasive diagnostic tests will be presented as a proportion with 90% confidence intervals | Throughout study completion, up to one year | |
Secondary | The association of ctDNA result (positive versus negative) and the PREVAIL-imaging pathway scoring result | The association between ctDNA result (positive versus negative) and the PREVAIL-imaging pathway scoring result will be assessed descriptively by presenting cross-tabulations and relevant proportions | Throughout study completion, up to one year | |
Secondary | Estimation of the cost of liquid biopsy in lieu of tissue biopsy as compared to standard of care investigations and treatments prioritisation | Simple estimation of the cost of liquid biopsy in lieu of tissue biopsy as compared to standard of care investigations and treatments prioritisation will be performed | Throughout study completion, up to one year | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 1a | Treatment response objective response rate | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 1b | Progression free survival | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 1c | Overall survival | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 2 | Proportion of patients who undergo a repeated invasive procedure | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 3a- comparison with NHS targets | Comparison of diagnostic pathway duration with NHS faster Diagnostic Standard (FDS) | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 3b- comparison with NHS targets | Comparison of diagnostic pathway duration with 62 day wait target | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 4a | Type of complications from invasive diagnostic procedures | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 4b | Frequency of complications from invasive diagnostic procedures | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 4c | Severity of complications from invasive diagnostic procedures | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 5 | Number and type of invasive procedures performed | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 5b | Number of histopathology reviews | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 5c | Number of tissue based NGS performed | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 6a | Healthcare costs associated with diagnostic pathway | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 6b | Cost per-quality adjusted-life-year of diagnostic pathway | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 6c | Number of hospital visits in diagnostic pathway | To run parallel for 12 months alongside the ACCESS implementation programme | |
Secondary | PREVAIL ctDNA Part 2 Study secondary end point 6d | Length of hospital stay during diagnostic pathway | To run parallel for 12 months alongside the ACCESS implementation programme |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Completed |
NCT03101566 -
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT05237193 -
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
|
||
Not yet recruiting |
NCT06037655 -
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
|
Phase 2 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Completed |
NCT00196105 -
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
|
N/A | |
Completed |
NCT02558959 -
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
|
Phase 2 | |
Completed |
NCT02829918 -
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
|
Phase 2 | |
Completed |
NCT02784353 -
Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy
|
N/A | |
Recruiting |
NCT05429203 -
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
|
N/A | |
Recruiting |
NCT02255669 -
Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction
|
N/A | |
Completed |
NCT01731821 -
Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
|
Phase 3 | |
Completed |
NCT00422409 -
Endoscopic Stenting of Gastrointestinal Cancer
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
Terminated |
NCT02615210 -
Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures
|
N/A | |
Completed |
NCT04595058 -
LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent
|
N/A | |
Recruiting |
NCT04856761 -
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
|
||
Recruiting |
NCT03427242 -
Apatinib for Advanced Biliary Carcinoma
|
Phase 2 | |
Recruiting |
NCT05615818 -
Personalized Medicine for Advanced Biliary Cancer Patients
|
Phase 3 |